Identifying Brain and Genetic Markers of Sertraline Treatment Response in People With Social Anxiety Disorder

Social anxiety disorder (SAD) is an anxiety disorder characterized by excessive fear and
avoidance of social situations. Selective serotonin reuptake inhibitors (SSRIs) are a
medication commonly prescribed to treat social anxiety disorder, but as many as 50% of
people with SAD do not respond to SSRIs. Current theory suggests that neurological
functioning and genetics may influence a patient's response to treatment. This study will
examine variations in genetics and brain reactivity among people with SAD who do and do not
respond to SSRIs. Through this, the study will identify neurological and genetic biomarkers
that can predict responsiveness to SSRI treatment in people with SAD.

Participation in this study will last 14 weeks. Both healthy people and people with SAD will
be recruited to participate. All participants will complete similar study visits at entry,
within 2 weeks of entry, and 12 weeks after that. The first visit, which will occur at study
entry, will include screening questionnaires, an interview with research staff, a medical
screening, a urine test, and collection of saliva samples for genotyping. The second visit
and the last visit, which will be separated by 12 weeks, will involve MRI scans and
behavioral tasks to be conducted inside and outside the MRI scanner. Over the 12 weeks
between MRI scanning sessions, participants with SAD will take sertraline, a common SSRI, on
a daily basis. They will also attend five additional visits during this time to complete
assessments of their symptoms. These visits will occur 1, 2, 4, 8, and 12 weeks after
starting sertraline treatment. Participants with SAD will therefore be completing a symptom
assessment, MRI scans, and behavioral tasks all on the final visit, 12 weeks after the
second visit.